Interim Clinical Commissioning Policy Statement: Rituximab for the treatment of Systemic Lupus Erythematosus in adults
September 2013
Reference: NHS ENGLAND A13/PS/a
<table>
<thead>
<tr>
<th>Directorate</th>
<th>Operations</th>
<th>Patients and Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nursing</td>
<td>Policy</td>
<td>Commissioning Development</td>
</tr>
<tr>
<td>Finance</td>
<td>Human Resources</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Publications Gateway Reference:</th>
<th>00407</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Purpose</td>
<td>Guidance</td>
</tr>
<tr>
<td>Document Name</td>
<td>Clinical Commissioning Policies and Clinical Commissioning Policy Statements</td>
</tr>
<tr>
<td>Author</td>
<td>Various, Medical Directorate, Specialised Services</td>
</tr>
<tr>
<td>Publication Date</td>
<td>10 September 2013</td>
</tr>
<tr>
<td>Target Audience</td>
<td>NHS England Regional Directors, NHS England Area Directors, Directors of Finance</td>
</tr>
</tbody>
</table>

| Additional Circulation List     | Clinical Reference Group Chairs |

| Description                     | Production of NHS England’s Clinical Commissioning Clinical Commissioning Policies and Clinical Commissioning Policy Statements |

| Cross Reference                 | N/A |
| Superseded Docs (if applicable) | N/A |
| Action Required                 | N/A |
| Timing / Deadlines (if applicable) | N/A |
| Contact Details for further information | Donna Hakes  
Medical Directorate, Specialised Services  
Skipton House  
London  
SE1 6LH  
07785 513461  
england.specialisedcommissioning@nhs.net |

**Document Status**

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet.
Clinical Commissioning Policy Statement: Rituximab for the treatment of Systemic Lupus Erythematosus in adults

First published: September 2013

Prepared by the NHS England Clinical Reference Group for Rheumatology

First published August 2013
Published by the NHS England, in electronic format only.
Background

There are approximately 15,000 people in England and Wales with SLE, predominately women, with a peak incidence at the age of 25-30 years old. The incidence and prevalence of SLE is higher in African-Caribbean, South Asian and Chinese populations compared to European whites (1,2). In these racial/ethnic groups the disease also tends to be more severe and in particular there is a higher incidence of renal involvement (3). SLE can affect any organ system, sequentially or at the same time. Effective management involves accurately assessing both disease activity and damage (i.e. permanent change) in all organ systems. There are several validated scoring systems for this purpose (BILAG 2004, SLEDAI-2K, SLICC), which are in use in specialised centres and in clinical trials (4-6). Renal involvement (glomerulonephritis) occurs in up to 40% of cases, has a key role in prognosis, and is associated with a higher mortality rate. It can occur many years after diagnosis, although is usually apparent within 5 years. Approximately 10% of patients with lupus nephritis develop end-stage renal failure requiring dialysis or transplantation.

The aim of drug therapy is to treat disease activity and prevent disease flares. Therapy is dictated by both organ involvement and severity of individual manifestations. Antimalarials (especially hydroxychloroquine), azathioprine and methotrexate, in combination with corticosteroids are commonly prescribed. These regimes are effective for the majority of patients who have mild-moderate skin and joint disease.

Approximately 20-30% of patients continue to have high disease activity despite these standard therapies or have organ involvement particularly associated with a worse prognosis e.g. renal, neuropsychiatric, haematological involvement. This group will require therapy with more potent immunosuppression such as intravenous cyclophosphamide or mycophenolate mofetil.

A proportion of these patients will however continue to have active uncontrolled disease despite these agents, or will have unacceptable toxicities from such drugs. In others, disease control will require an unacceptably high dose of corticosteroids which, in this population, is associated with the development of significant
Co-morbidities such as bone, cardiovascular and metabolic consequences (7,8). These patients will require access to both specialised clinical advice and access to treatment with a biologic drug such as rituximab. Rituximab is currently used in specialised centres in England in this clinical setting, and there is an existing national registry, the BILAG Biologics Register (www.bilagbr.org). Currently, less than 10% of all cases of SLE have disease of a severity requiring such an approach. The aim of this policy statement is to make access to the drug equitable across the country for the specific groups of patients indicated.

<table>
<thead>
<tr>
<th>Commissioning position</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rituximab</strong> will only be funded for use in Systemic Lupus Erythematosus (SLE) where the following criteria are met:</td>
</tr>
</tbody>
</table>

1. Diagnosis of SLE (fulfilling either ACR or SLICC criteria) AND;
2. Active disease (defined as at least one BILAG A score and/or 2B scores, or a SLEDAI-2K score >6) AND;
3. Failure to respond or having adverse events to, two or more standard immunosuppressive therapies (one of which must be either mycophenolate mofetil or cyclophosphamide, unless contraindicated) in combination with corticosteroids. A failed response is defined as being unable to achieve sustained disease control and still having evidence of at least one BILAG A or at least 2 BILAG B scores (or requiring unacceptably high levels of long term oral corticosteroids to maintain a lower disease activity state).
4. All patients who meet the above criteria of refractory disease activity sufficient to justify the use of rituximab, must be managed at, or in collaboration, with a centre commissioned to provide specialised services that has expertise in the assessment and management of SLE.
5. All patients receiving rituximab for SLE must be registered with the BILAG Biologics Register (www.bilagbr.org).

All SLE patients with refractory disease activity should also be given the opportunity to be considered for clinical trials assessing therapies for the treatment of active SLE.

**Response Definition**

Response to therapy should be assessed by 6 months for non-renal disease and at 6 and 12 months for patients with lupus nephritis. These definitions of response are based on validated outcome measures utilised in the most recent SLE clinical trials.

For **non-renal disease** a clinically meaningful response by 6 months will be defined as:

- ILAG A scores reduced to a B score or less AND BILAG B
scores reduced to C or D.

- ND/OR SLEDAI-2K reduced by 4 or more points from baseline.

- or renal disease: a response will be assessed at 6 and 12 months, and by 12 months a response will be defined as:

  - 50% improvement in proteinuria and normalisation or stabilisation of eGFR from baseline values.

Any response should also occur in the context of either a stable or reduced steroid dose requirement compared to baseline, especially in the 8 weeks prior to the 6-month clinical assessment.

**Dosing Regimes**

In England, the main protocol in use is:

IV rituximab 1000 mg on day 1 and 15 of an infusion cycle (with or without low dose cyclophosphamide). After which patients are retreated if they have been deemed a responder and when they are developing a further flare of disease (9). For re-treatment of such patients, re-treatment is permitted if the clinician assessment is that a flare is now beginning, even if the BILAG score criteria for initial therapy is not yet achieved (e.g. recurrence of one or more B scores without waiting for an A score). This is necessary because severe flares carry a risk of further organ damage for the patient.

**Effective from**

August 2013

**Evidence summary**

The beneficial effects of Rituximab in active SLE, refractory to standard immunosuppression, have been reported in 24 case series from specialised lupus centres throughout the world, including England. There is a consistency of reported improvement across all case series, despite use of different end points. Use of Rituximab in this setting is also recommended within Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association recommendations for the management of adult and paediatric lupus nephritis published November 2012 (16).

There have been two RCTs of Rituximab in SLE, the LUNAR (Lupus Nephritis Assessment with Rituximab) and EXPLORER (Exploratory Phase 2/3 SLE Evaluation of Rituximab) studies, which enrolled 144 and 257 patients with non-renal and renal disease respectively (10,11). Although neither study achieved their primary end-point, it is recognised that there were important design limitations in these trials, including issues with end-point measurements, the very high use of concomitant steroids in combination with other immunosuppressives in both treatment arms, as well as being underpowered to detect a clinically
meaningful improvement (12,17,18).

More importantly, there are also significant differences between the subjects that were enrolled in these two studies, and the patient cohort proposed in this commissioning policy, namely, patients with refractory disease in whom standard of care treatment has failed. The clinical trials added rituximab on top of standard therapy for non-refractory patients, and also those patients who had failed standard therapies (cyclophosphamide) were excluded from the trials, as were patients with severe organ-threatening manifestations (12). Usual practice in England is to withdraw background immunosuppression when initiating rituximab (9).

Despite these limitations, pre-specified secondary analyses did suggest efficacy of rituximab in several patient subsets, including significantly fewer (p< 0.01) patients in the rituximab group requiring cyclophosphamide for worsening disease. There were also serological improvements, with significant effects on anti-dsDNA antibodies and complement levels. Both these tests are sensitive bloodstream markers of lupus-specific disease activity. This is an important observation, because improvement in these parameters is known to be a predictor of clinical response, and also support biological efficacy of rituximab.

Recent open-label studies strongly support the clinical efficacy of rituximab particularly in the group of refractory SLE populations to whom this commissioning policy will apply. Lu et al studied 50 patients, and of 45 patients with adequate follow-up, 19 (42%) achieved remission at the 6 month time point (9). Li et al studied patients with lupus nephritis treated with rituximab with or without cyclophosphamide (13). Of the 19 patients recruited 4 (21%) had a complete response at 48 weeks using the SLICC Renal Response Criteria. 11 (58%) had a partial response and 4 patients (22%) were stable or worsened at 48 weeks. A case series of 164 patients with biopsy proven lupus nephritis from England and Spain, the majority of whom had refractory or relapsing disease, reported a complete or partial response (>50% improvement in all renal parameters) in 67% of patients at 6 months after rituximab (14). A recent systematic analysis of studies in refractory lupus nephritis (300 patients) reported a complete or partial response in 67-87% of patients, according to lupus nephritis subtype (20).

Similarly, a meta-analysis of 188 patients from open-label studies noted an overall 91% response rate within the cases reported and even an 89.3% response in patients with CNS involvement (15).

Efficacy has also been reported amongst 136 patients in the French Autoimmunity and Rituximab registry of patients with both renal and non-renal disease, with improvements in articular, cutaneous, renal and haematological manifestations (19).

Although there are important limitations of open-labelled studies, the overall experience of the use of rituximab in refractory lupus is
that there is a definite efficacy of this agent in patients that have failed conventional combination therapy (corticosteroids, hydroxychloroquine and immunosuppressants). Whilst the magnitude of improvement in individual patients is variable, there is clear evidence that rituximab offers an important therapeutic option for people living with severe SLE that has been refractory to existing conventional therapies.

**Equality impact**
Throughout the production of this document, due regard has been given to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited in under the Equality Act 2010) and those who do not share it.

**Responsible CRG**
Rheumatology CRG

**Mechanism for Funding**
Funding is transacted as per local contract agreements and terms.

**Date Approved by Clinical Priorities Advisory Group**
12 July 2013

**Policy review date**
During 2014

**References**


